1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. Summary
    OPS   CA6838231083

OPSENS INC.

(OPS)
  Report
Delayed Toronto Stock Exchange  -  05/13 03:59:55 pm EDT
1.810 CAD   +9.70%
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
05/09/2022 05/10/2022 05/11/2022 05/12/2022 05/13/2022 Date
1.72(c) 1.64(c) 1.63(c) 1.65(c) 1.81(c) Last
221 986 83 655 51 277 233 968 105 201 Volume
-10.42% -4.65% -0.61% +1.23% +9.70% Change
More quotes
Estimated financial data (e)
Sales 2022 36,6 M 28,3 M 28,3 M
Net income 2022 -7,29 M -5,64 M -5,64 M
Net Debt 2022 - - -
P/E ratio 2022 -26,8x
Yield 2022 -
Sales 2023 54,4 M 42,0 M 42,0 M
Net income 2023 1,70 M 1,31 M 1,31 M
Net Debt 2023 - - -
P/E ratio 2023 60,3x
Yield 2023 -
Capitalization 196 M 152 M 152 M
Capi. / Sales 2022 5,36x
Capi. / Sales 2023 3,61x
Nbr of Employees 163
Free-Float 95,0%
More Financials
Company
OpSens Inc. provides fiber optic sensing technology. The Company operates through two segments: Medical and Industrial. The Medical segment focuses on physiological measurement, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications... 
More about the company
Ratings of Opsens Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about OPSENS INC.
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
04/13TRANSCRIPT : Opsens Inc., Q2 2022 Earnings Call, Apr 13, 2022
CI
04/13OPSENS : CEO Certification
PU
04/13OPSENS : CFO Certification
PU
04/13Opsens Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Februa..
CI
04/13OpSens Swings to Loss in Fiscal Q2 as Consolidated Sales Drop
MT
04/13OPSENS BRIEF : Net loss was $2.4 million in Q2 2022 compared with a net income of $41,000 ..
MT
04/13OPSENS BRIEF : Consolidated sales were $8.1 million in Q2 2022, compared with $8.8 million..
MT
04/13Opsens announces second quarter fiscal 2022 financial results
AQ
04/06Opsens to host second quarter fiscal year 2022 financial results conference call on wed..
AQ
03/14OpSens to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 15th t..
AQ
02/25OpSens Reports on Voting Results from its Annual Shareholders Meeting
AQ
02/09Opsens appoints brad davis as new chief commercial officer
AQ
More news
News in other languages on OPSENS INC.
04/26Opsens Inc. Annonce l'approbation de Santé Canada pour son nouveau fil-guide TAVR
04/13Opsens Inc. annonce ses résultats pour le deuxième trimestre et les six mois terminés l..
04/13OpSens subit une perte au deuxième trimestre de l'exercice financier alors que les vent..
02/09OpSens Inc. nomme Brad Davis au poste de chef de la direction commerciale
02/01OpSens Inc. annonce l'extension du contrat d'approvisionnement de 4 ans d'Abiomed jusqu..
More news
Analyst Recommendations on OPSENS INC.
More recommendations
Chart OPSENS INC.
Duration : Period :
Opsens Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPSENS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,81 CAD
Average target price 4,22 CAD
Spread / Average Target 133%
EPS Revisions
Managers and Directors
Louis Laflamme President, Chief Executive Officer & Director
Robin Villeneuve Chief Financial Officer & Secretary
Alan W. Milinazzo Executive Chairman
Jean Lavigueur Independent Director
Denis L. Harrington Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OPSENS INC.-41.61%152
THERMO FISHER SCIENTIFIC-18.86%211 945
DANAHER CORPORATION-24.26%178 394
INTUITIVE SURGICAL, INC.-37.74%80 295
SIEMENS HEALTHINEERS AG-17.38%63 485
EDWARDS LIFESCIENCES CORPORATION-24.70%60 652